Episode Details
Back to EpisodesAdvances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic
Episode 26
Published 4 months ago
Description
As the management of patients with ESR1-mutated metastatic breast cancer evolves,
various questions have emerged in clinical practice. “It's a complex situation,” explains
Hope S. Rugo, MD, division chief of breast medical oncology and the Women's Cancers
Program director at the City of Hope Comprehensive Cancer Center in Duarte,
California. She discusses how recent advances have changed treatment decisions with
Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at
Cedars-Sinai Cancer in Los Angeles. “I think it's important to keep in mind that today we
just have single-agent oral SERDs, and people like to give combinations,” Dr. Rugo
notes. But what combinations to give and when remains unclear. “I think how we're
going to decide is that we're going to wait and see what's approved and then look at
patients to try and figure out what to do,” she offers.
various questions have emerged in clinical practice. “It's a complex situation,” explains
Hope S. Rugo, MD, division chief of breast medical oncology and the Women's Cancers
Program director at the City of Hope Comprehensive Cancer Center in Duarte,
California. She discusses how recent advances have changed treatment decisions with
Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at
Cedars-Sinai Cancer in Los Angeles. “I think it's important to keep in mind that today we
just have single-agent oral SERDs, and people like to give combinations,” Dr. Rugo
notes. But what combinations to give and when remains unclear. “I think how we're
going to decide is that we're going to wait and see what's approved and then look at
patients to try and figure out what to do,” she offers.